BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Condition: T-Acute Lymphoblastic Leukemia; Adult T Lymphoblastic Lymphoma
MeSH terms: Lymphoma; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Intervention: BL-8040; Nelarabine
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 12.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      The outcome of patients with relapsed or refractory adult T-acute lymphoblastic leukemia
      (T-ALL) and the related disease T-lymphoblastic lymphoma (T-LBL) is extremely poor with 30%
      of the patients responding to first salvage therapy and long-term survival of only 10%.
      Therefore, novel therapies for patients with relapsed/refractory T-ALL/LBL represent an unmet
      clinical need.

      Recent data provide strong evidence that CXCR4 signaling plays a major role in T-cell
      leukemia cell maintenance and leukemia initiating activity, and targeting CXCR4 signaling in
      T-ALL cells reduces tumor growth in an animal model. In this study, the investigators propose
      that the addition of BL-8040 to nelarabine as a salvage therapy for patients with
      relapsed/refractory T-ALL/LBL will result in a higher complete remission (CR) rate than
      nelarabine alone without an increase in toxicity and will allow patients to proceed to a
      potentially curative allogeneic hematopoietic cell transplant.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of T-acute lymphoblastic leukemia/ lymphoblastic lymphoma according to WHO
             criteria which has relapsed or is refractory to chemotherapy.

          -  Peripheral blood lymphoblasts ≤ 50,000 mcL. Hydroxyurea and/or leukapheresis is
             permitted to reduce the peripheral blast count prior to enrollment and treatment.

          -  Age ≥ 18 years

          -  ECOG performance status ≤ 2.

          -  Adequate organ function defined as:

               -  Calculated creatinine clearance ≥ 50 ml/min using the Cockroft-Gault formula

               -  AST, ALT, total bilirubin ≤ 2 x institutional ULN except for Gilbert's disease or
                  when in the opinion of treating physician elevated levels are due to direct
                  involvement of leukemia (e.g., hepatic infiltration or biliary obstruction due to
                  leukemia), in which case ALT and AST may be elevated up to ≤ 5 x IULN.

          -  Women of childbearing potential and men must agree to use adequate contraception with
             a highly effective method (hormonal or barrier method of birth control, abstinence)
             prior to study entry and for the duration of study participation. Abstinence is
             acceptable if this is the established and preferred contraception for the subject.

          -  Female subjects must have a negative urine or serum pregnancy test within 72 hours
             prior to start of study treatment if of childbearing potential or be of
             non-childbearing potential. If the urine test is positive or cannot be confirmed as
             negative, a serum pregnancy test will be required. The serum pregnancy test must be
             negative for the subject to be eligible. Non-childbearing potential is defined as:

             *≥ 45 years of age and has not had menses for > 2 years

               -  Amenorrheic for > 2 years without a hysterectomy and oophorectomy and a FSH value
                  in the postmenopausal range upon pretrial (screening) evaluation

               -  Post-hysterectomy, oophorectomy, or tubal ligation. Documented hysterectomy or
                  oophorectomy must be confirmed with medical records of the actual procedure or
                  confirmed by an ultrasound. Tubal ligation must be confirmed with medical records
                  of the actual procedure.

          -  Able to understand and willing to sign an IRB-approved written informed consent
             document.

        Exclusion Criteria:

          -  Previous treatment with nelarabine for relapsed or refractory disease.

          -  Pregnant or nursing.

          -  Received any other investigational agent or systemic cytotoxic chemotherapy within the
             preceding 2 weeks.

          -  Active CNS involvement with leukemia

          -  Active HIV or hepatitis B or C infection.

          -  Any medical condition which, in the opinion of the clinical investigator, would
             interfere with the evaluation of the patient. Subjects with a clinically significant
             or unstable medical or surgical condition or any other condition that cannot be
             well-controlled by the allowed medications permitted in the study protocol that would
             preclude safe and complete study participation, as determined by medical history,
             physical examinations, laboratory tests, and according to the investigator's judgment.